A new COVID-19 medication has been approved in Abu Dhabi for the treatment of mild to moderate cases and those who have had direct contact with a patient.
The emirate's Department of Health (DoH) has partnered with Swiss healthcare company Roche to provide casirivimab and imdevimab to certain categories of patients.
The antibody combination has already been approved in the European Union and Japan, and conditionally approved in the UK and Australia.
It is also authorised for emergency use in the United States, India, Switzerland and Canada, and is recommended by the World Health Organisation (WHO).
.@DoHSocial has partnered with Swiss healthcare company @Roche to provide a new Covid-19 medication, approved for emergency use, to treat mild to moderate Covid-19 cases and those who have had direct contact with a positive case.
— مكتب أبوظبي الإعلامي (@ADMediaOffice) December 1, 2021
Read more: https://t.co/vGQXyUvhGB pic.twitter.com/Yj9JxVgemP
UAE launches 'Abu Dhabi Call to Action' on environmental crime
H.H. Sheikh Hamdan approves strategy for Dubai Longevity Authority
Sheikh Abdullah attends UAE Youth Dialogue at UN General Assembly
UAE delegation holds economic, health talks at UN General Assembly
UAE signs judicial agreements at UN Crime Congress in Abu Dhabi
UAE workshop discusses priorities for People of Determination strategy
UAE highlights need to protect food supplies from global disruptions
Saif bin Zayed meets justice, interior ministers on crime congress sidelines
